

朱传娴

客户顾问

hzhu@acs-i.org

SciFinder文献检索难点解析

2017.12



提纲

- SciFinder文献检索难点解析
 - 如何获得更全面的结果集
 - 利用Index Term修正检索词
 - 巧用CAS Role
 - 善用Categorize
 - 避免标引时差引起的漏检

SciFinder检索——文献检索

■ 文献检索方法

- 主题检索
- 作者名检索
- 机构名检索
- 文献标识符检索
- 期刊名称和专利信息（公开号，申请号等）
- 从物质，反应获得文献



■ 检索策略推荐

- 关注某特定领域的文献：主题检索
- 关注物质有关的文献：先获得物质，再获得文献
- 关注某科研人员的文献：作者名检索
- 关注某机构科研进展：机构名检索

浏览结果集发现关键词

主题检索：阿奇霉素的结构修饰


检索式：Modification of Azithromycin

The screenshot displays the SciFinder web interface. At the top, there is a 'CAS Solutions' dropdown menu and the SciFinder logo with the tagline 'A CAS SOLUTION'. Below this is a navigation bar with three tabs: 'Explore' (selected), 'Saved Searches', and 'SciPlanner'. On the left side, there is a sidebar with two main sections: 'REFERENCES' and 'SUBSTANCES'. Under 'REFERENCES', there is a list of search criteria: 'Research Topic', 'Author Name', 'Company Name', 'Document Identifier', 'Journal', 'Patent', and 'Tags'. Under 'SUBSTANCES', there is a list: 'Chemical Structure' and 'Markush'. The main content area is titled 'REFERENCES: RESEARCH TOPIC' with a help icon. It features a search input field containing the text 'Modification of Azithromycin'. Below the input field, there are 'Examples:' listed as 'The effect of antibiotic residues on dairy products' and 'Photocyanation of aromatic compounds'. A blue 'Search' button is positioned below the examples. At the bottom of the main area, there is a link for 'Advanced Search'.

关键词之间用介词连接：in, with, of...

浏览结果集发现关键词

CAS Solutions

 **SCIFINDER**
A CAS SOLUTION

Preferences | SciFinder Help | Sign Out

Welcome Helen Zhu

Explore

Saved Searches

SciPlanner

Research Topic "Modification of Azithromycin"

REFERENCES ?

Select All Deselect All

1 of 5 Research Topic Candidates Selected

	References
<input type="checkbox"/> 4 references were found containing "Modification of Azithromycin" as entered.	4
<input checked="" type="checkbox"/> 182 references were found containing the two concepts "Modification" and "Azithromycin" closely associated with one another.	182
<input type="checkbox"/> 630 references were found where the two concepts "Modification" and "Azithromycin" were present anywhere in the reference	630
<input type="checkbox"/> 2965409 references were found containing the concept "Modification".	2965409
<input type="checkbox"/> 18550 references were found containing the concept "Azithromycin".	18550

Get References

“Concepts”表示对主题词做了同义词的扩展；

“Closely associated with one another”表示同时出现在一个句子中；

“were present anywhere in the reference”表示同时出现在一篇文献中；

Save：保存结果集于服务器上，方便随时查看

获得检索结果集之后首先要随机浏览记录，判断是否是相关文献、是否符合检索要求、是否有更好的关键词，如有必要需要调整检索式

浏览结果集发现关键词

10. Azithromycin antimicrobial derivatives with non-antibiotic pharmaceutical effect

By: Gardarsson, Friarik; Guldberg, Susanne; Gardarsson, Magnus
Assignee: Iceland

The invention provides mols., which are based on a modification of azithromycin, removing the antibiotic effect, while retaining other beneficial effects, such as, but not limited to immunomodulatory effects. The compds. of the invention can be described by compds. of Formula (I) as further defined herein.

Patent Information

Patent No.		Kind	Language	Date	Application No.	Date
US 20160031925	PATENTPAK	A1		Feb 4, 2016	US 2015-14783245	Oct 8, 2015
WO 2014166503	PATENTPAK	A1	English	Oct 16, 2014	WO 2014-DK50092	Apr 10, 2014

Priority Application

IS 2013-50050	A	Apr 10, 2013
WO 2014-DK50092	W	Apr 10, 2014

Indexing

Carbohydrates (Section33-7)

Section cross-reference(s): 1, 10, 63

Concepts

Bronchiolitis

diffuse panbronchiolitis; prepn. of azithromycin antimicrobial derivs. with non-antibiotic pharmaceutical effect

Adult respiratory distress syndrome	Antiasthmatics
Antibacterial agents	Antibiotics
Antimicrobial agents	Asthma
Bacterial infection	Bronchitis
Chronic bronchitis	Chronic obstructive pulmonary disease
Crohn disease	Cystic fibrosis
Immune disease	Immunomodulators
Inflammation	Inflammatory bowel disease
Intestine	Macrolide antibiotics
Rheumatoid arthritis	

Substances

1092100-82-7P

prepn. of azithromycin antimicrobial derivs. with non-antibiotic pharmaceutical effect

Catalyst use; Synthetic preparation; Preparation; Uses

586967-35-3P

1349581-16-3P

1631161-49-3P

1631161-50-6P

1631161-51-7P

1631161-52-8P

1631161-53-9P

1631161-54-0P

prepn. of azithromycin antimicrobial derivs. with non-antibiotic pharmaceutical effect

获得重要相关词，可再次检索

浏览结果集发现关键词

The screenshot displays the SciFinder web interface. At the top, the navigation bar includes 'Explore', 'Saved Searches', and 'SciPlanner'. The search topic is 'Research Topic "derivative of azithromycin"'. The left sidebar shows 'REFERENCES' and 'SUBSTANCES' sections. The main content area shows a list of references, with the first one selected: '1. Toward the rational design of macrolide antibiotics to combat resistance'. A 'Tools' dropdown menu is open, highlighting 'Combine Answer Sets'. A dialog box titled 'Combine Answer Sets' is also open, showing a table of saved answer sets and options to combine them.

SciFinder Interface Elements:

- Navigation: Explore, Saved Searches, SciPlanner
- Search Topic: Research Topic "derivative of azithromycin"
- Left Sidebar: REFERENCES, SUBSTANCES
- Main Content: REFERENCES: RESEARCH TOPIC
- Search Input: derivative of azithromycin
- Tools Menu: Remove Duplicates, Combine Answer Sets, Add Tag
- Combine Answer Sets Dialog: Select saved answer set(s) to combine with your current answer set (312).
- Table in Dialog:

Answer Set	Date Saved
Azm sub (97)	Jul 14, 2017
Opened saved answer set "Autosaved Substance Set" (5227) > keep analysis "Bioactivity Indicators" (2461) > get references (13726) > refine by categories	
Azi Substructure (30)	Jul 13, 2017
Chemical Structure substructure with limiters > substances (100) > get references (30)	
modification of Azithromycin (137)	Jul 13, 2017
Research Topic "Modification of Azithromycin" > references (137)	
石杉碱甲 (185)	Jun 5, 2017
Substance Identifier "102518-79-6" > substances (1) > 102518-79-6 > get references (185)	

Combine Answer Sets Dialog Options:

- Combine: Include all answers from both sets
- Intersect: Include only answers that appear in both sets
- Exclude: Include only answers from current answer set (312) that are not in modification of Azithromycin (137)
- Exclude: Include only answers from modification of Azithromycin (137) that are not in current answer set (312)

浏览结果集发现关键词

CAS Solutions

SCI FINDER[®]
A CAS SOLUTION

Preferences | SciFinder Help | Sign Out

Welcome Helen Zhu

Explore | Saved Searches | SciPlanner

Save | Print | Export

Research Topic "derivative of azithromycin" > references (2) | "modification of Azithromycin (...)" (440) > Synthesis and antibacterial ac...

REFERENCES

Get Substances | Get Reactions | Get Related Citations | Tools

Create Keep Me Posted Alert | Send to SciPlanner

Analyze | Refine | Categorize

Sort by: Accession Number

0 of 440 References Selected

Display Options

Analyze by: Author Name

Ma Shutao	18
Alihodzic Sulejman	14
Lazarevski Gorjana	11
Shen Shunyi	11
Ge Han	10
Kobrehel Gabrijela	7
Mutak Stjepan	7
Cong Chao	6
Li Xin	6
Cui Wenping	5

- 1. Carbamoylated azithromycin incorporated zirconia hybrid monolith for enantioseparation of acidic chiral drugs using non-aqueous capillary electrochromatography**
Q Quick View | Other Sources
By Dixit, Shuchi; Lee, Il Seung; Park, Jung Hag
From Journal of Chromatography A (2017), 1507, 132-140. | Language: English, Database: CAPLUS
Carbamoylated derivs. of two antibiotics, namely, clindamycin phosphate (CLIP) and erythromycin (ERY) were successfully employed as co-precursors, in combination of zirconium tetrabutoxide as a precursor, to prep. chiral org.-zirconia hybrid monoliths (i.e., CLIP-ZHMs and ERY-ZHMs, resp.) via a single-step in-situ sol-gel approach in our previous works. Their superiority over chiral org.-zirconia/silica monoliths, prepd. by post-modification approach, in terms of better enantioresoln. and enhanced stability inspired us to prep. ZHMs based on an another antibiotic, azithromycin (i.e., AZI-ZHMs...
- 2. Toward the rational design of macrolide antibiotics to combat resistance**
Q Quick View | Other Sources
By Pavlova, Anna; Parks, Jerry M.; Oyelere, Adegboyega K.; Gumbart, James C.
From Chemical Biology & Drug Design (2017), Ahead of Print. | Language: English, Database: CAPLUS
Macrolides, 1 of the most prescribed classes of antibiotics, bind in the bacterial ribosome's polypeptide exit tunnel and inhibit translation. However, mutations and other ribosomal modifications, esp. to the base A2058 of the 23S rRNA, have led to a growing resistance problem. Here, we have used mol. dynamics simulations to study the macrolides erythromycin and azithromycin in wild-type, A2058G-mutated, and singly or doubly A2058-methylated Escherichia coli ribosomes. The ribosomal modifications result in less favorable interactions between the base 2058 and the desosamine sugar of the mac...
- 3. Fructose injection of antibiotic medicine**
Q Quick View | PATENTPAK
By Cai, Ying
From Faming Zhuanli Shenqing (2017), CN 106668862 A 20170517. | Language: Chinese, Database: CAPLUS

获得全面的结果集是做好文献调研的首要条件
SciFinder提供强大的文献处理工具，帮助处理文献

利用Inder Term选词

主题检索：植物中天然活性成分的抗癌研究

检索式：Natural Active Component with Anti Cancer



The screenshot displays the SciFinder web interface. At the top, there is a navigation bar with 'CAS Solutions' and the SciFinder logo. Below this, a menu bar contains 'Explore', 'Saved Searches', and 'SciPlanner'. The left sidebar is divided into two main sections: 'REFERENCES' and 'SUBSTANCES'. Under 'REFERENCES', there is a list of search criteria including 'Research Topic', 'Author Name', 'Company Name', 'Document Identifier', 'Journal', 'Patent', and 'Tags'. The 'Research Topic' option is currently selected. The main content area is titled 'REFERENCES: RESEARCH TOPIC' and features a search input field containing the text 'Natural Active Component with Anti Cancer'. Below the input field, there are example search terms: 'The effect of antibiotic residues on dairy products' and 'Photocyanation of aromatic compounds'. A blue 'Search' button is positioned below the examples. At the bottom of the main content area, there is a link for 'Advanced Search'.

关键词之间用介词连接：in, with, of...

主题检索的候选项

CAS Solutions

SciFINDER[®]
A CAS SOLUTION

Preferences | SciFinder Help | Sign Out

Welcome Helen Zhu

Explore | Saved Searches | SciPlanner

Research Topic "Natural Active Component with ..."

REFERENCES ⓘ

Select All Deselect All

1 of 4 Research Topic Candidates Selected

	References
<input checked="" type="checkbox"/> 153 references were found containing the two concepts "Natural Active Component" and "Anti Cancer" closely associated with one another.	153
<input type="checkbox"/> 349 references were found where the two concepts "Natural Active Component" and "Anti Cancer" were present anywhere in the reference.	349
<input type="checkbox"/> 4863 references were found containing the concept "Natural Active Component".	4863
<input type="checkbox"/> 1216569 references were found containing the concept "Anti Cancer".	1216569

Get References

只有153篇吗？

“Concepts”表示对主题词做了同义词的扩展；

“Closely associated with one another”表示同时出现在一个句子中；

“were present anywhere in the reference”表示同时出现在一篇文献中；

利用Index Term选词

CAS Solutions

SciFINDER[®]
A CAS SOLUTION

Preferences | SciFinder Help | Sign Out

Welcome Helen Zhu

Explore | Saved Searches | SciPlanner

Save | Print | Export

14 duplicates were automatically removed.

Research Topic "Natural Active Component with ..." > references (139)

REFERENCES ?

Get Substances | Get Reactions | Get Related Citations | Tools

Create Keep Me Posted Alert | Send to SciPlanner

Analyze | Refine | Categorize

Sort by: Accession Number

0 of 139 References Selected

Analyze by: Author Name

Zhang Yaozhou 4

Chen Jianqing 3

Chen Yujiao 3

Cheng Yiyu 3

Cui Jinsong 3

Dou Jing 3

Ge Zhiwei 3

He Qing 3

Huo Yang 3



Liu Li 3

1. Preparation of staple food containing graviola extract
PATENTPAK
By Jung, Chan Yeong
From Repub. Korean Kongkae Taeho Kongbo (2016), KR 2016117102 A 20161010. | Language: Korean, Database: CAPLUS
The authors describes an edible food contained graviola ext., which can increase the immune system in the human body and help to eliminate harmful toxic **components** in the human body by the **natural anti-cancer** agents, such as phytochems., acetylcholinesterase and acetogenin as **active** ingredient contained in graviola. Edible foods such as boiled rices, the mixed rice, the rice rolled in dried laver, noodles, Udong, knife-cut noodle, the clear soup with wheat flakes, instant noodle, rice-cake soup, cakes and breads are manufd. through mixing and kneading brown rice, flour, corn, soybean, potato,...

2. Effects of psoralen as an anti-tumor agent in human breast cancer MCF-7/ADR cells
PATENTPAK
By Wang, Xiaohong; Cheng, Kai; Han, Yong; Zhang, Guoqiang; Dong, Jianli; Cui, Yuzhen; Yang, Zhenlin
From Biological & Pharmaceutical Bulletin (2016), 39(5), 815-822. | Language: English, Database: CAPLUS
Psoralen is a major **active component** of Psoralea corylifolia. In the present study, we analyzed psoralen-induced changes in human breast **cancer** MCF-7/ADR cells and investigated the underlying mechanisms of the **anticancer** effect on MCF-7/ADR cells. We measured cell viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to evaluate the cytotoxicity and multidrug resistance (MDR) reversal **activity** of psoralen. The cell cycle distribution and apoptosis, accumulation and efflux of rhodamine123 (Rh123), and P-glycoprotein (P-gp) expression levels of MCF-7/ADR cells ...

3. Skin care liquid containing snake and chinese medicine extract.
PATENTPAK
By Cheng, Jinxue; Cheng, Gang; Zhu, Jieying

利用Index Term选词



Index Term基于内容的分析工具，发现natural products, Pharmaceutical 这个和天然活性成分很相关的词

是否用这个词去检索，效果会更好？

利用Index Term选词

Explore ▾ Saved Searches ▾ SciPlanner

Research Topic "Natural Active Component with ..." > references (139)

REFERENCES

- Research Topic
- Author Name
- Company Name
- Document Identifier
- Journal
- Patent
- Tags

SUBSTANCES

Chemical Structure

Mar

REFERENCES: RESEARCH TOPIC ?

Natural Product with anti cancer

Examples:
The effect of antibiotic residues on dairy products
Photocyanation of aromatic compounds

Search

Advanced Search

新的检索式:

Natural Product with anti cancer

REFERENCES ?

Select All Deselect All

1 of 5 Research Topic Candidates Selected

	References
<input type="checkbox"/> 19 references were found containing "Natural Product with anti cancer" as entered.	19
<input checked="" type="checkbox"/> 9987 references were found containing the two concepts "Natural Product" and "anti cancer" closely associated with one another.	9987
<input type="checkbox"/> 43362 references were found where the two concepts "Natural Product" and "anti cancer" were present anywhere in the reference.	43362
<input type="checkbox"/> 464095 references were found containing the concept "Natural Product".	464095
<input type="checkbox"/> 1216569 references were found containing the concept "anti cancer".	1216569

Get References

更换检索词后，结果放大近70倍

STN中的CAS Role

ANST Analytical Study

Analyte	ANT
Analytical Matrix	AMX
Analytical Reagent Use	ARG
Analytical Role, Unclassified	ARU

PREP Preparation

Bioindustrial Manufacture	BMF
Biosynthetic Preparation	BPN
Byproduct	BYP
Industrial Manufacture	IMF
Preparation, Unclassified	PNU
Purification or Recovery	PUR
Synthetic Preparation	SPN

PROC Process

Biochemical Process	BCP
Biological Process	BPR
Geological or Astronomical Process	GPR
Physical, Engineering, or Chemical Process	PEP
Removal or Disposal	REM

BIOL Biological Study

Adverse Effect, Including Toxicity	ADV
Agricultural Use	AGR
Biological Activity or Effector, Except Adverse	BAC
Biochemical Process	BCP
Bioindustrial Manufacture	BMF
Biological Occurrence	BOC
Biosynthetic Preparation	BPN
Biological Process	BPR
Biological Study, Unclassified	BSU
Biological Use, Unclassified	BUU
Cosmetic Use	COS
Diagnostic Use	DGN
Food or Feed Use	FFD
Natural Product Occurrence	NPO
Pharmacological Activity	PAC
Pharmacokinetics	PKT
Therapeutic Use	THU

STN中的CAS Role

FORM Formation, Nonpreparative

Formation, Unclassified FMU

Geological or Astronomical Formation GFM

NANO Nanomaterial

OCCU Occurrence

Biological Occurrence BOC

Geological or Astronomical Occurrence GOC

Natural Product Occurrence NPO

Occurrence, Unclassified OCU

Pollutant POL

RACT Reactant or Reagent

Reactant RCT

Reagent RGT

USES Uses

Agricultural Use AGR

Analytical Reagent Use ARG

Biological Use, Unclassified BUU

Catalyst Use CAT

Cosmetic Use COS

Diagnostic Use DGN

Food or Feed Use FFD

Modifier or Additive Use MOA

Other Use, Unclassified NUU

Polymer in Formulation POF

Technical or Engineered Material Use TEM

Therapeutic Use THU

巧用CAS Role

查找纯化双氧水（7722-84-1）的文献

Explore ▼ Saved Searches ▼ SciPlanner

Substance Identifier "7722-84-1" > substances (1)

REFERENCES

- Research Topic
- Author Name
- Company Name
- Document Identifier
- Journal
- Patent
- Tags

REFERENCES: RESEARCH TOPIC ?

purify of 7722-84-1

Examples:
The effect of antibiotic residues on dairy products
Photocyanation of aromatic compounds

Explore ▼ Saved Searches ▼ SciPlanner

SUBSTANCES Research Topic "purify of 7722-84-1"

- Chemical Structure
- Markush

REFERENCES ?

Select All Deselect All

1 of 4 Research Topic Candidates Selected

- ☒ 2126 references were found containing the two concepts "purify" and "7722-84-1" closely associated with one another.
- ☐ 17336 references were found where the two concepts "purify" and "7722-84-1" were present anywhere in the reference.
- ☐ 2457989 references were found containing the concept "purify".
- ☐ 271782 references were found containing the concept "7722-84-1".

Get References

巧用CAS Role

1. A method for a kind of tailwater cascade oxidation depth purification [Machine Translation].

By: Liu, Fuqiang; Luo, Kun; Shuang, Chendong; Hu, Dabo; Zhao, Wei; Jiang, Bicun; Yan, Tingting; Li, Jianhua; Li, Aimin
Assignee: Nanjing University, Peop. Rep. China

[Machine Translation of Descriptors]. The invention discloses a kind of biochem. oxidn. cascade tail water depth purifn. method, belongs to biochem. tail water depth treatment tech. field. The present invention firstly adopts ferrous and hydrogen peroxide to carry out oxidn. to participate in the pre-oxidn., then using subsequent preliminary sedimentation stage when pH is 2.5~ 6 formed on iron mud waste water adsorption and flocculation, remove part of org. and inorg. phosphorus, Reduce photocatalytic oxidn. strengthen weakened section of org. and inorg. phosphorus load impact; further use of catalytic oxidn. depth to remove orgs., strengthen the subsequent secondary sedimentation stage pH as 6-9, the formation of iron mud back to pre-oxidn. section, as a catalyst recycling, reduce medicine consumption and low sludge amt. The present invention also play the pre-oxidn. zone hydroxyl free radical reaction is quick and has broad-spectrum resistance characteristics, and effectively utilizes neutralization pptn. when different pH scope formed iron mud adsorption characteristics and catalytic activity, significantly improves the reaction efficiency, low reagent consumption, and effectively realize the recycling of iron mud.

Patent Information

Patent No.	Kind	Language	Date	Application No.	Date
CN 106007080	A		Oct 12, 2016	CN 2016-10521105	Jul 1, 2016

Priority Application

CN 2016-10521105	Jul 1, 2016
------------------	-------------

Indexing

Waste Treatment and Disposal (Section60)

Concepts

Adsorption
Sludges

Recycling
pH

a method for a kind of tailwater cascade oxidn. depth purifn. [Machine Translation].

Substances

1333-74-0 Hydrogen 🔍

7439-89-6 Iron 🔍

7722-84-1 Hydrogen peroxide (H2O2) 🔍



7723-14-0 Phosphorus 🔍

a method for a kind of tailwater cascade oxidn. depth purifn. [Machine Translation].

Pollutant; Removal or disposal; Occurrence; Process

噪音信息

巧用CAS Role

CAS Solutions ▼ **SciFINDER**
A CAS SOLUTION

Preferences | SciFinder Help ▼ Sign Out

Welcome Helen Zhu

Explore ▼ Saved Searches ▼ SciPlanner Save Print Export

Research Topic "purify of 7722-84-1" > **references (2126)** > Method for preparing light wei...

REFERENCES ?

Get Substances Get Reactions Get Related Get Tools

Analyze **Refine** **Categorize**

Sort by: Accession Number ▼

☐ 0 of 2126 References Selected

Analyze by: ?

Author Name ▼

Jiang Wenlan	30
Xu Qinghua	30
Xu Shengying	30
Yuan Changbing	30
Yuan Xin	28
Kagawa Kenkichi	23
Odo Tsunahiro	18
Saito Tomomi	18
Tanaka Toshio	18
Mabuchi Kimihiro	12

☐ 21. **Zinc oxide concentrate purification**
Quick View PATENTPAK ▼
By Yu, Qiongpeng
From Faming Zhuanli Shenqing (2016), CN 105...
The present invention discloses a zinc oxide concentrate purification method, comprising: evapn. and concn., the prepn. of pre-concentrate, the prepn. of concentrate under condition, high product uniformity, low loss.

☐ 22. **Systematic comparison of conventional and novel purification methods for SWCNT**
Quick View Other Sources
By Clancy, Adam J.; White, Edward R.; Tay, Hu
From Carbon (2016), 108, 423-432. | Language: English
As-synthesized single-walled carbon nanotubes (SWCNTs) are contaminated with residual catalyst particles. These contaminants have a detrimental effect on the effective mech. and elec. properties of SWCNTs. In this work, a systematic series of SWCNT purifications including acid treatments, oxidative treatments, and other methods were performed on SWCNT type (Tuball). Each of the purification procedures was evaluated for its effectiveness in removing catalyst particles.

☐ 23. **Method for preparing light weight high-efficient supported photocatalyst for air purifier**
Quick View PATENTPAK ▼
By Yang, Lixin
From Faming Zhuanli Shenqing (2016), CN 105797705 A 20160727. | Language: Chinese, Database: CAPLUS
The title method comprises immersing photocatalyst hydrosol by a light wt. carrier, and prepg. light wt. high-efficient supported photocatalyst for air purifier. The prepn. method

Save This Answer Set

* Required

Save:

☒ All answers
☐ Only selected answers

Title: *

purify of H2O2

Description:

OK Cancel

Display Options

Page: 2 of 107

巧用CAS Role

0 of 1 Substance Selected

1. 7722-84-1

~222048

OH—OH

H₂O₂
Hydrogen peroxide (H₂O₂)

► **Key Physical Properties**
Regulatory Information
Experimental Properties

Get References

Limit results to:

<input type="checkbox"/> Adverse Effect, including toxicity	<input checked="" type="checkbox"/> Preparation
<input type="checkbox"/> Analytical Study	<input type="checkbox"/> Process
<input type="checkbox"/> Biological Study	<input type="checkbox"/> Properties
<input type="checkbox"/> Combinatorial Study	<input type="checkbox"/> Prophetic in Patents
<input type="checkbox"/> Crystal Structure	<input type="checkbox"/> Reactant or Reagent
<input type="checkbox"/> Formation, nonpreparative	<input type="checkbox"/> Spectral Properties
<input type="checkbox"/> Miscellaneous	<input type="checkbox"/> Uses
<input type="checkbox"/> Occurrence	

For each sequence, retrieve:

☐ Additional related references, e.g., activity studies, disease studies.

Get Cancel

巧用CAS Role

CAS Solutions Preferences | SciFinder Help Sign Out

SciFinder
A CAS SOLUTION

Welcome Helen Zhu

Explore **Saved Searches** **SciPlanner** Save Print Export

Substance Identifier "7722-84-1" > substances (1) > get references (14672)

REFERENCES Get Substances Get Reactions Get Related Citations Tools

Analyze **Refine** **Categorize**

Sort by: Accession Number

0 of 14672 References Selected

Remove Duplicates
Combine Answer Sets
Add Tag

1. **Hydrogen peroxide working solution continuous preparation apparatus [Machine Translation]**
Quick View
By Li, Wanqing; Zhou, Xu
From Shiyong Xinxing Zh

2. **Immobilization of D-amino acid oxidase on mu**
Quick View
By Li, Rong; Sun, Jian; Fu
From Catalysts (2016), 6

Yamanaka Ichiro 31
Mi Zhentao 30
Kiely Christopher J 28
Brillas Enric 27

Combine Answer Sets
Select saved answer set(s) to combine with your current answer set (14672):

43 Answer Sets 1 Selected

Reference Answer Set Details	Date Saved
<input checked="" type="checkbox"/> purify of H2O2 (2126) Research Topic "purify of 7722-84-1" > references (2126)	Oct 19, 2016
<input type="checkbox"/> remove 6 (6) Research Topic "remove of 123-39-7" > references (49) > refine by categories	Oct 19, 2016
<input type="checkbox"/> purify of 7722-84-1 (2124) Research Topic "purify of 7722-84-1" > references (2124)	Oct 17, 2016
<input type="checkbox"/> remove 123-39-7 (9) (9) Substance Identifier "123-39-7" > substances (1) > get references (384) > Combine Reference Answer Sets "remove DMF 49 (49)" (9)	Oct 17, 2016

Select an option for combining the answer sets:


- ☒ **Combine** Include all answers from both sets
- ☐ **Intersect** Include only answers that appear in both sets
- ☐ **Exclude** Include only answers from **current answer set (14672)** that are not in **purify of H2O2 (2126)**
- ☐ **Exclude** Include only answers from **purify of H2O2 (2126)** that are not in **current answer set (14672)**

Combine Answer Sets Cancel

DER
A CAS SOLUTION

巧用CAS Role

CAS Solutions

**SCIFINDER**
A CAS SOLUTION

Preferences | SciFinder Help | Sign Out

Explore | Saved Searches | SciPlanner | Save | Print | Export

Substance Identifier "7722-84-1" > substances (1) > get references (14672) > Combine Reference Answer Sets "purify of H2O2 (2126)" (305)

REFERENCES

Get Substances | Get Reactions | Get Related Citations | Tools

Create Keep Me Posted Alert | Send to SciPlanner

Analyze | Refine | Categorize

Analyze by: Author Name

Tanaka Fujio	7
Minamikawa Yoshitsugu	6
Murakami Shinichi	6
Kajiwarra Shoichiro	5
Nagai Kazunori	5
Gao Weiping	4
Kaga Tadayoshi	4
Kokubu Jun	4
Luan Guoyan	4
Murakami Seishi	4

Sort by: Accession Number

0 of 305 References Selected

Display Options

Page: 1 of 16

☐ 1. Hydrogen peroxide purification adsorbent preparation method

Quick View PATENTPAK

By Wang, Qiyu
From Faming Zhuanli Shenqing (2016), CN 105749877 A 20160713. | Language: Chinese, Database: CAPLUS

The invention relates to a hydrogen peroxide purifn. adsorbent prepn. method. The method comprises: using o-fluorobenzoyl group modification to obtain composite functional resin, introducing strong-withdrawing electron group 4-fluorobenzoyl Me to form antioxidant group to improve the life of the resin in the hydrogen peroxide oxidn. conditions, and introducing fluorine-contg. group to enhance corrosion resistance of the resin skeleton. The sphere surface is protected, thus extending the life.

☐ 2. Device and method for generating oxidants in situ for water purifn.

Quick View PATENTPAK

By Xia, Zijun; Sui, Caroline Chihyu; Xu, Yida; Zhang, Xing; Huang, Qunjian; Vasconcellos, Stephen Robert; Salerno, Michael Brian
From PCT Int. Appl. (2016), WO 2016106630 A1 20160707. | Language: Chinese, Database: CAPLUS

A method of reducing the org. compds. in an aq. stream by generating an oxidant in-situ using ≥ 1 electrolytic cell. The method may comprise contacting at least a portion of the aq. stream with the electrolytic cell. The electrolytic cell may have ≥ 2 electrodes, in which ≥ 1 electrode is a metal electrode and, a power source for powering the ≥ 2 electrodes. A H_2O treatment system for generating an oxidant in-situ comprising ≥ 1 electrolytic cell. The electrolytic cell may have ≥ 2 electrodes, in which ≥ 1 electrode is a metal electrode, and a power source for powering the ≥ 2 electrodes. A metho...

☐ 3. Residue purification recovery device

Quick View PATENTPAK

By Li, Wanqing; Zhou, Xuejun; Liu, Jiqian; Gao, Chuanping; She, Linyuan
From Faming Zhuanli Shenqing (2016), CN 105565275 A 20160511. | Language: Chinese, Database: CAPLUS

The title residue purifn. recovery device comprises a separator, an intermediate tank, a recovery tank, a cooler, a refined canister, a

浏览记录，判断是否符合要求

巧用CAS Role



1. Hydrogen peroxide purification adsorbent preparation method

By: Wang, Qiyu

Assignee: Wang, Jinming, Peop. Rep. China

The invention relates to a hydrogen peroxide purifn. adsorbent prepn. method. The method comprises: using o-fluorobenzoyl group modification to obtain composite functional resin, introducing strong-withdrawing electron group 4-fluorobenzoyl Me to form antioxidant group to improve the life of the resin in the hydrogen peroxide oxidn. conditions, and introducing fluorine-contg. group to enhance corrosion resistance of the resin skeleton. The sphere surface is protected, thus extending the life.

Patent Information

Patent No.	Kind	Language	Date	Application No.	Date
CN 105749877	 PATENTPAK	A	Jul 13, 2016	7722-84-1P Hydrogen peroxide, preparation 	Page 2 in PATENTPAK
Priority Application				hydrogen peroxide purifn. adsorbent prepn. method	
CN 2015-10852280				Purification or recovery; Preparation	


8. Method of purifying hydrogen peroxide using reverse osmosis membrane and ion exchangers

By: Myung, Jung Jae

Assignee: Dongwoo Fine-Chem Co., Ltd., S. Korea

The invention relates to a method of purifying H_2O_2 by using a reverse osmosis membrane which is a C nanomaterial-coated porous polymer scaffolds, an anion exchange resin and a cation exchange resin. More specifically, the invention relates to a method of purifying H_2O_2 characterized by passing H_2O_2 through a cation exchange resin and an anion exchange resin after passing through a reverse osmosis membrane coated with C nanomaterials over porous polymer scaffolds.



7722-84-1P Hydrogen peroxide (H_2O_2), preparation 	Page 2 in PATENTPAK
method of purifying hydrogen peroxide using reverse osmosis membrane and ion exchangers	
Purification or recovery; Preparation	

都是需要的文献

善用Categorize

检索文献：

1. 去除N-甲基甲酰胺（123-39-7）的文献？
2. 用N-甲基甲酰胺（123-39-7）作洗脱剂的文献？

善用Categorize

去除N-甲基甲酰胺（123-39-7）

Explore ▼ Saved Searches ▼ SciPlanner

REFERENCES

- Research Topic
- Author Name
- Company Name
- Document Identifier
- Journal
- Patent
- Tags

REFERENCES: RESEARCH TOPIC ?

remove of 123-39-7

Examples:
The effect of antibiotic residues on dairy products
Photocyanation of aromatic compounds

Explore ▼ Saved Searches ▼ SciPlanner

SUBSTANCES

- Chemical Research Topic "remove of 123-39-7"
- Markush

REFERENCES ?

Select All Deselect All

1 of 4 Research Topic Candidates Selected

- ☒ 49 references were found containing the two concepts "remove" and "123-39-7" closely associated with one another.
- ☐ 264 references were found where the two concepts "remove" and "123-39-7" were present anywhere in the reference.
- ☐ 2808271 references were found containing the concept "remove".
- ☐ 4512 references were found containing the concept "123-39-7".

Get References

善用Categorize

1. Removal of gas phase dimethylamine and N,N-dimethylformamide using non-thermal plasma

By: Wang, Wenzheng; Fan, Xing; Zhu, Tianle; Wang, Haining; Ye, Daiqi; Hong, Xiaowei

Dimethylamine (DMA) and N,N-dimethylformamide (DMF) are typical N-VOCs exhausted from manufg. factories. In the present study, the behavior of non-thermal plasma (NTP) was systematically investigated for removal of gas-phase DMA and DMF in a link tooth wheel-cylinder plasma reactor. Exptl. results show that DMA is much easier to be decompd. by NTP than DMF. Coexisting DMF has no effect on DMA conversion while DMF conversion is significantly promoted by the addn. of DMA. Regardless of initial gas compns. as well as DMA and DMF concn., CO_x selectivity increased monotonously with increasing ED. But CO_x selectivity of 100% cannot be obtained even with ED higher than 70 J L⁻¹, indicating the formation of org. intermediates during DMA and DMF decompn. Based on org. products anal. with GC-MS and mol. optimization results with d. functional theory calcn., possible mechanisms on DMA and DMF degrdn. were proposed. The org. products from DMA and DMF decompn. by NTP were found to have great soly. and high biodegradability. Thus, NTP enhanced absorption/biol. method is suggested for complete removal of DMA and DMF.

Indexing

Air Pollution and Industrial Hygiene (Section59-4)

Concepts

Absorption	Air pollution control
Bond energy	Bond length
Decomposition	Decomposition catalysts
Plasma	Waste gas treatment








removal of gas phase dimethylamine and N,N-dimethylformamide using non-thermal plasma


Volatile organic compounds


removal of gas phase dimethylamine and N,N-dimethylformamide using non-thermal plasma

Removal or disposal; Process

Substances

56-40-6 Glycine, formation (nonpreparative) 
 64-18-6 Formic acid, formation (nonpreparative) 
 75-12-7 Formamide, formation (nonpreparative) 
 79-20-9 Methyl acetate 
 105-37-3 Ethyl propionate 
 107-31-3 Methyl formate 
 123-39-7 N-Methyl formamide 



144-62-7 Oxalic acid, formation (nonpreparative) 

removal of gas phase dimethylamine and N,N-dimethylformamide using non-thermal plasma

Formation, unclassified; Formation, nonpreparative

需要的文献

善用Categorize

3. Removing agent containing alkylamide mixture

By: Li, Bo; Yu, Ran

Assignee: Qingdao Hui Cheng Petrochemical Technology Co., Ltd., Peop. Rep. China

The present invention relates to a kind of alkylamide removing agent. The removing agent comprises N-methylformamide 50-70 wt.%, N, N-dimethyl acetamide 30-50 wt.% and water as balance. The alkylamide removing agent of the present invention has water compatibility, and has no corrosivity for copper or copper alloy, and is generally nontoxic to mankind and environment. Because the constituent of alkylamide removing agent only comprises two main constituents, the removing agent after use can be easily by fractionation and recombine to original formula, and can be recycled to apply in the prepn. process to achieve the effect of reducing cost and environmental protection. The present invention also provides a method of using the removing agent of the present invention to remove photoresist.

Patent Information

Patent No.	Kind	Language	Date	Application No.	Date
CN 104698775	PATENTPAK	A	Jun 10, 2015	CN 2013-10646205	Dec 4, 2013

Priority Application

CN 2013-10646205	Dec 4, 2013
------------------	-------------

Indexing

Radiation Chemistry, Photochemistry, and Photographic and Other Reprographic Processes (Section74-5)

Concepts

Coating removers

Photoresists

removing agent contg. alkylamide mixt.


Amides

removing agent contg. alkylamide mixt.

Other use, unclassified; Physical, engineering or chemical process; Process; Uses

Substances

123-39-7 N-Methylformamide



127-19-5 N, N-Dimethyl acetamide

removing agent contg. alkylamide mixt.

Other use, unclassified; Physical, engineering or chemical process; Process; Uses

噪音信息更多，如何去除？



善用Categorize

CAS Solutions
SciFINDER[®]
A CAS SOLUTION

Preferences | SciFinder Help | Sign Out

Welcome Helen Zhu

Explore | Saved Searches | SciPlanner

Save | Print | Export

Research Topic "remove of 123-39-7" > references (49) > Removing agent containing alky...

REFERENCES

Get Substances | Get Reactions | Get Related Citations | Tools

Create Keep Me Posted Alert | Send to SciPlanner

Analyze | Refine | **Categorize**

Sort by: Accession Number

Display Options

☐ 0 of 49 References Selected

Analyze by:

Author Name

Egbe Matthew I	4
Hara Yasushi	4
Takahashi Fumiharu	4
Bang Sun Hong	2
Hong Heon Pyo	2
Legenza Michael Walter	2
Ward Irl E	2
Albrecht Herbert	1
Alsters Paul	1
Aoba Kazuhiro	1

☐ 1. **Removal of gas phase dimethylamine and N,N-dimethylformamide using non-thermal plasma**
Quick View | Other Sources
By Wang, Wenzheng; Fan, Xing; Zhu, Tianle; Wang, Haining; Ye, Daiqi; Hong, Xiaowei
From Chemical Engineering Journal (Amsterdam, Netherlands) (2016), 299, 184-191. | Language: English, Database: CAPLUS
Dimethylamine (DMA) and N,N-dimethylformamide (DMF) are typical N-VOCs exhausted from manufg. factories. In the present study, the behavior of non-thermal plasma (NTP) was systematically investigated for **removal** of gas-phase DMA and DMF in a link tooth wheel-cylinder plasma reactor. Exptl. results show that DMA is much easier to be decompd. by NTP than DMF. Coexisting DMF has no effect on DMA conversion while DMF conversion is significantly promoted by the addn. of DMA. Regardless of initial gas compns. as well as DMA and DMF concn., CO_x selectivity increased monotonously with increasing E...

☐ 2. **Stripping composition for removing photoresist and a method, for peeling photoresist, using same**
Quick View | PATENTPAK
By Park, Tae Moon; Jung, Dae Chul; Lee, Dong Hoon; Lee, Woo Ram; Lee, Hyun Jun; Kim, Ju Young
From PCT Int. Appl. (2016), WO 2016027985 A1 20160225. | Language: Korean, Database: CAPLUS
The present invention relates to a stripping compn. for **removing** a photoresist and a method, for peeling a photoresist, using same, the stripping compn. comprising: one or more amine compds.; an amide-based compd. substituted with one or two of C1-5 straight or branched alkyl groups; a polar org. solvent; a particular triazole-based compd.; and a benzimidazole-based compd.

☐ 3. **Removing agent containing alkylamide mixture**
Quick View | PATENTPAK
By Li, Bo; Yu, Ran
From Faming Zhuanli Shenqing (2015), CN 104698775 A 20150610. | Language: Chinese, Database: CAPLUS
The present invention relates to a kind of alkylamide **removing** agent. The **removing** agent comprises N-methylformamide 50-70 wt.%, N, N-dimethyl acetamide 30-50 wt.%

善用Categorize

Categorize ?

1. Select a heading and category.

2. Select index terms of interest.

Category Heading	Category	Index Terms	Selected Terms
All	Substances in technology (824)	<div>Select All Deselect All</div> <div> <input checked="" type="checkbox"/> N-Methyl formamide 6 <input type="checkbox"/> N,N-Dimethylformamide 3 <input type="checkbox"/> Copper 2 <input type="checkbox"/> Copper alloy 2 <input type="checkbox"/> Dimethylamine 2 <input type="checkbox"/> Formamide 2 <input type="checkbox"/> Oxides (inorganic) 2 <input type="checkbox"/> Polyimides 2 <input type="checkbox"/> 1-Fluoro-1,2,2-trichloroethane 1 <input type="checkbox"/> 2,3-Dimethyl-1-butanol 1 <input type="checkbox"/> 2,4-Di-tert-butylphenol 1 <input type="checkbox"/> 2,6-Di-tert-butyl-1,4-benzoquinone 1 <input type="checkbox"/> 2-(Methyl mercapto)benzothiazole 1 </div>	

 Click 'x' to remove the category from 'Selected Terms' ☒ Technology > Formed, removed, & other substances (1 Terms) ☐ || Technology | Materials & products (76) | | |
General chemistry	Formed, removed, & other substances (61)		
Physical chemistry	Metallurgy (45)		
Biotechnology	Processes & apparatus (35)		
Polymer chemistry	Imaging & recording (4)		
Environmental chemistry	Power & fuel topics (5)		
Synthetic chemistry	Ceramics (2)		
Catalysis	Construction (2)		
Genetics & protein chemistry			
Biology			
Analytical chemistry			

Technology > Formed, removed, & other substances > 1 Index Term(s) Selected

OK

Cancel

避免标引时差引起的漏检

Update frequency

- Updated daily
- Patent references from **nine major issuing authorities** available within two days from the time the patent was issued

9大核心专利机构发布的
专利2日内收录进
SciFinder

Bibliographic information and abstracts for all articles in more than 1,500 key scientific journals are added to CAplusSM within 7 days. The list below is sorted alphabetically by the full journal title and also includes the journal abbreviation and CODEN. This is not the full list of publications covered by CAS, and the list is subject to change.

核心期刊的文献7日内
收录进SciFinder

对核心期刊及核心专利机构发布的专利的标引在2-3周内完成

在收录至标引期间的文献可能会漏检！

避免标引时差引起的漏检

检索治疗肝病的药物Daclatasvir的相关文献

SciFinder

Research Topic "Daclatasvir" > references (575) > references (2015-2) (50) > Management of hepatitis C

REFERENCES

Research Topic
Author Name
Company Name
Document Identifier
Journal
Patent
Tags

SUBSTANCES

Chemical Structure
Markush
Molecular Formula
Property
Substance Identifier

Opened saved answer set "Daclatasvir-1" (308)

REFERENCES

Get Substances Get Reactions Get Related Citations Tools

Analyze Refine Categorize

Sort by: Accession Number

0 of 308 References Selected

Analyze by: Author Name

Author Name	Count
Gao Min	32
Mcphee Fiona	29
Meanwell Nicholas A	20
Fridell Robert A	18
Lemm Julie A	18
Sun Jin Hua	18
Wang Chunfu	17
Belema Makonen	16
O Boyle Donald R II	15
Hernandez Dennis	12

- Daclatasvir plus sofosbuvir for HCV in patients coinfecting with HIV-1**
Quick View Other Sources
By Wyles, D. L.; Ruane, P. J.; Sulkowski, M. S.; Dieterich, D.; Luetkemeyer, A.; Morgan, T. R.; Sherman, K. E.; Dretter, R.; Fishbein, D.; Gathe, J. C., Jr.; et al
From New England Journal of Medicine (2015), 373(8), 714-725. | Language: English, Database: CAPLUS
Background: The combination of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and the NS5B inhibitor sofosbuvir has shown efficacy in patients with HCV mono-infection. Data are lacking on the efficacy and safety of this combination in patients coinfecting with human immunodeficiency virus type 1 (HIV-1). Methods: This was an open-label study involving 151 patients who had not received HCV treatment and 52 previously treated patients, all of whom were coinfecting with HIV-1. Previously untreated patients were randomly assigned in a 2:1 ratio to receive either 12 wk or 8 wk of daclatasvir...
- Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients**
Quick View Other Sources
By Dietz, Julia; Susser, Simone; Berkowski, Caterina; Perner, Dany; Zeuzem, Stefan; Sarrazin, Christoph
From PLoS One (2015), 10(8), e0134395/1-e0134395/17. | Language: English, Database: CAPLUS
Different highly effective interferon-free treatment options for chronic hepatitis C virus (HCV) infection are currently available. Pre-existence of resistance associated variants (RAVs) to direct antiviral agents (DAAs) reduces sustained virologic response (SVR) rates by 3-53% in hepatitis C virus (HCV) genotype 1 infected patients depending on different predictors and the DAA regimen used. Frequencies of single and combined resistance to NS3, NS5A and NS5B inhibitors and consequences for the applicability of different treatment regimens are unknown. Parallel population based sequencing of HCV N...
- The novel cyclophilin inhibitor CPI-431-32 concurrently blocks HCV and HIV-1 infections via a similar mechanism of action**
Quick View Other Sources
By Gallay, Philippe A.; Bobardt, Michael D.; Chatterji, Udayan; Trepanier, Daniel J.; Ure, Daren; Cosme, Foster, Robert
From PLoS One (2015), 10(8), e0134707/1-e0134707/18. | Language: English, Database: CAPLUS

通过检索物质获得文献准确，但是不够新



SciFinder®
A CAS SOLUTION

避免标引时差引起的漏检

The screenshot displays the SciFinder web interface. At the top, the 'Research Topic "Daclatasvir" > references (575) > Safety and efficacy of dual di...' path is visible. The left sidebar shows navigation options like 'REFERENCES', 'SUBSTANCES', and 'Analyze by:'. The main content area lists search results, with the first result highlighted: '1. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis'. The interface includes various toolbars for refining results, such as 'Get Substances', 'Get Reactions', and 'Get Related Citations'. The bottom of the interface shows the SciFinder logo and the text 'A CAS SOLUTION'.

Research Topic "Daclatasvir" > references (575) > Safety and efficacy of dual di...

REFERENCES

Research Topic
Author Name
Company Name
Document Identifier
Journal
Patent
Tags

SUBSTANCES

Chemical Structure
Markush

SciFinder®

Explore Saved Searches SciPlanner

Research Topic "Daclatasvir" > references (575) > Safety and efficacy of dual di...

REFERENCES

Analyze Refine Categorize

Analyze by:

Author Name

McPhee Fiona 68

Gao Min 32

Chayama Kazuaki 30

Hernandez Dennis 25

Meanwell Nicholas A 25

Eley Timothy 23

Kumada Hiromitsu 22

Hughes Eric A 21

Pol Stanislas 21

Ishikawa Hiroki 20

Get Substances Get Reactions Get Related Citations Tools

Create Keep Me Posted Alert Send to SciPlanner

Sort by: Accession Number

0 of 575 References Selected

1. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis

Quick View Other Sources

By Toyoda, Hindeori; Kumada, Takashi; Tada, Toshifumi; Takaguchi, Koichi; Ishikawa, Toru; Tsuji, Kunihiro; Zeniya, Mikio; Iio, Etsuko; Tanaka, Yasuhito
From Journal of Gastroenterology (2016), Ahead of Print. | Language: English, Database: CAPLUS

Background: Hepatitis C virus (HCV) infection is a major comorbidity in patients receiving hemodialysis. Interferon-based antiviral therapy to eradicate HCV is less effective in patients receiving hemodialysis than patients without renal dysfunction. Recently reported combination therapy with two oral direct-acting antiviral drugs, **daclatasvir** and asunaprevir, both of which are metabolized in the liver and excreted into the bile ducts, reportedly showed a high rate of HCV eradication. We evaluated the safety and efficacy of this therapy in patients receiving hemodialysis. Methods: The safe...

2. Management of hepatitis C patients with decompensated liver disease

Quick View Other Sources

By Hsu, Ching-Sheng; Kao, Jia-Horng
From Expert Review of Gastroenterology & Hepatology (2016), Ahead of Print. | Language: English, Database: CAPLUS

Little is known about the tolerance and effectiveness of novel oral direct acting antivirals (DAA) in hepatitis C patients with decompensated cirrhosis. To examine the studies relevant to the treatment of hepatitis C virus(HCV)-related decompensated liver disease, we performed computer-based searches for English articles between 1947 and August 2015. Fourteen articles including HCV patients with decompensated cirrhosis were reviewed. The combinations of ledipasvir(LDV)/sofosbuvir(SOF)/ribavirin(RBV) for 12 wk, or **daclatasvir**/SOF/RBV for 12 wk are safe and effective for HCV genotype 1 or 4 i...

3. Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro

Quick View Other Sources

By Galani, Boris Rosnay Tietcheu; Sahuc, Marie-Emmanuelle; Sass, Gabriele; Njayou, Frederic Nico; Loscher, Christine; Mkounga, Pierre; Deloison, Gaspard; Brodin, Priscille; Rouille, Yves; Tiegs, Gisa; et al
From Archives of Virology (2016), Ahead of Print. | Language: English, Database: CAPLUS

SciFinder®

A CAS SOLUTION

通过主题直接检索物质名称，发现最新的文献



避免标引时差引起的漏检

The screenshot displays the SciFinder web interface. On the left, a 'Refine by' sidebar is open, showing options like 'Research Topic', 'Author', 'Company Name', 'Document Type', 'Publication Year', 'Language', and 'Database'. The 'Publication Year' section is selected, showing a range from 1995 to 1995. The main interface shows a search for 'Research Topic "Daclatasvir" > references (575) > refine "2016-" (58) > The clinical features of patie...'. The results are sorted by 'Accession Number' and show 0 of 58 references selected. The first three references are listed:

- 1. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis**
By Toyoda, Hindeori; Kumada, Takashi; Tada, Toshifumi; Takaguchi, Koichi; Ishikawa, Toru; Tsuji, Kunihiro; Zeniya, Mikio; Iio, Etsuko; Tanaka, Yasuhiro
From Journal of Gastroenterology (2016), Ahead of Print. | Language: English, Database: CAPLUS
Background: Hepatitis C virus (HCV) infection is a major comorbidity in patients receiving hemodialysis. Interferon-based antiviral therapy to eradicate HCV is less effective in patients receiving hemodialysis than patients without renal dysfunction. Recently reported combination therapy with two oral direct-acting antiviral drugs, **daclatasvir** and asunaprevir, both of which are metabolized in the liver and excreted into the bile ducts, reportedly showed a high rate of HCV eradication. We evaluated the safety and efficacy of this therapy in patients receiving hemodialysis. Methods: The safe...
- 2. Management of hepatitis C patients with decompensated liver disease**
By Hsu, Ching-Sheng; Kao, Jia-Horng
From Expert Review of Gastroenterology & Hepatology (2016), Ahead of Print. | Language: English, Database: CAPLUS
Little is known about the tolerance and effectiveness of novel oral direct acting antivirals (DAA) in hepatitis C patients with decompensated cirrhosis. To examine the studies relevant to the treatment of hepatitis C virus(HCV)-related decompensated liver disease, we performed computer-based searches for English articles between 1947 and August 2015. Fourteen articles including HCV patients with decompensated cirrhosis were reviewed. The combinations of ledipasvir(LDV)/sofosbuvir(SOF)/ribavirin(RBV) for 12 wk, or **daclatasvir**/SOF/RBV for 12 wk are safe and effective for HCV genotype 1 or 4 i...
- 3. Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro**
By Galani, Borris Rosnay Tietcheu; Sahuc, Marie-Emmanuelle; Sass, Gabriele; Njayou, Frederic Nico; Loscher, Christine; Mkounga, Pierre; Deloison, Gaspard; Brodin, Priscille; Rouille, Yves; Tiegs, Gisa; et al
From Archives of Virology (2016), Ahead of Print. | Language: English, Database: CAPLUS

通过PY限定最新的文献，与通过物质检索获得的结果集合并

避免标引时差引起的漏检

1. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis

By: Toyoda, Hindeori; Kumada, Takashi; Tada, Toshifumi; Takaguchi, Koichi; Ishikawa, Toru; Tsuji, Kunihiko; Zeniya, Mikio; Iio, Etsuko; Tanaka, Yasuhito

Background: Hepatitis C virus (HCV) infection is a major comorbidity in patients receiving hemodialysis. Interferon-based antiviral therapy to eradicate HCV is less effective in patients receiving hemodialysis than patients without renal dysfunction. Recently reported combination therapy with two oral direct-acting antiviral drugs, **daclatasvir** and asunaprevir, both of which are metabolized in the liver and excreted into the bile ducts, reportedly showed a high rate of HCV eradication. We evaluated the safety and efficacy of this therapy in patients receiving hemodialysis. Methods: The safety and viral responses were compared among patients infected with HCV genotype 1, between 28 patients receiving hemodialysis, and propensity score-matched 56 patients without renal dysfunction. Results: The redn. in serum HCV RNA levels 1 day after the start of therapy was significantly larger ($p = 0.0329$) and the disappearance of serum HCV RNA occurred significantly earlier ($p = 0.0017$) in patients receiving hemodialysis than those without renal dysfunction. The rates of sustained viro. response, i.e., the eradication of HCV, were comparable between two groups; the rate of SVR12 was 100 % in patients receiving hemodialysis and 94.6 % in patients without renal dysfunction. No adverse constitutional events were obsd. in either of the groups. The elevation of serum alanine aminotransferase levels, a known adverse effect of these drugs, was obsd. in comparable rate of patients between the two groups. Conclusions: The therapy with **daclatasvir** and asunaprevir has high antiviral efficacy in patients receiving hemodialysis with

Indexing

Pharmacology (Section1)

Citations

Anon; Tada T, Kumada T, Toyoda H, et al Viral eradication reduces all-cause mortality in patients with hepatitis C virus genotype 1b. *Hepatology*, 10.1002/hep.22545 2008, 48, 1690 [Q](#)
Chayama, K; *Hepatology*, 10.1002/hep.24724 2012, 55, 724 [Q](#)
Deltens, P; *Alim Pharmacol Ther*, 10.1111/j.1365-2036.2011.04741.x 2011, 34, 454 [Q](#)
Espinosa, M; *Nephrol Dial Transplant*, 10.1093/ndt/16.8.1669 2001, 16, 1669 [Q](#)

17. The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay

By: Kan, Toshi; Hashimoto, Senju; Kawabe, Naoto; Murao, Michihito; Nakano, Takuji; Shimazaki, Hiroaki; Nakaoka, Kazunori; Ohki, Masashi; Takagawa, Yuka; Kurashita, Takamitsu; Takamura, Tomoki; Yoshioka, Kentaro

Background: Resistance-assocd. variants (RAVs) reduce the efficacy of interferon (IFN)-free therapy with asunaprevir and **daclatasvir** for patients infected with hepatitis C virus (HCV) genotype 1b. The characteristics of patients with an L31 or a Y93 variant in the nonstructural 5A region detected by a polymerase chain reaction invader assay were investigated. Methods: In total, 201 patients with HCV genotype 1b were examd. for L31F/M/V variants or a Y93H variant by the polymerase chain reaction invader assay. Results: L31M and Y93H variants were detected in 4.6 and 21.4 % of patients, resp. Patients with an L31M variant had no significant characteristics. Patients with a Y93H variant had significantly higher HCV RNA levels (6.5 ± 0.5 log copies per mL vs 6.1 ± 0.7 log copies per mL, $p = 0.0002$), higher frequency of mutant type of the IFN-sensitivity-detg. region (88.4% vs 71.7% , $p = 0.0251$), and higher frequency of TT genotype at rs8099917 of IL28B (91.7% vs 54.3% , $p < 0.0001$) than those with Y93 wild-type strains. Multivariate anal. identified HCV RNA levels [odds ratio (OR) 3.72, 95 % confidence interval (CI) 1.71-8.06, $p = 0.0009$] and TT genotype at rs8099917 (OR 7.45, 95 % CI 2.11-26.4, $p = 0.0018$) as factors assocd. with the presence of a Y93H variant. Conclusion: The presence of a Y93H variant was assocd. with higher HCV RNA levels and TT genotype at rs8099917 of IL28B. Thus, patients with a Y93H variant may be ideal candidates for IFN-based therapy rather than IFN-free therapy, although the high viral load of these patients may reduce the response rate of IFN-based therapy.

Indexing

Immunochemistry (Section15-2)

Section cross-reference(s): 3

Concepts

Animal gene

IL28B; clin. features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay

Biological study, unclassified; Properties; Biological study

Aging, animal
Genetic polymorphism
Hepatitis C
Homo sapiens
Immunotherapy
Sex
Blood platelet
Genotypes
Hepatitis C virus
Human
Leukocyte

Substances

57-88-5 Cholesterol, biological studies [Q](#)
60-27-5 Creatinine [Q](#)
635-65-4 Bilirubin, biological studies [Q](#)
9000-86-6 Alanine aminotransferase [Q](#)
9000-97-9 Aspartate aminotransferase [Q](#)
9001-26-7 Prothrombin [Q](#)
9004-61-9 Hyaluronic acid [Q](#)
9046-27-9 γ -GTP [Q](#)

clin. features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay

Biological study, unclassified; Biological study

标引未完成

目标物质未做重点研究



文献检索练习

- 检索“多功能载药蛋白纳米粒”的文献。被引次数最高的文献来自哪份期刊？发文最多的研究机构是哪家？该研究领域专利多还是期刊多？在中国发文最多的机构是哪一家？其中研究紫杉醇（paclitaxel）的有多少文献？
- 检索中药五味子的相关文献。找出分析五味子素（Schisandrin）的相关文献
- 检索你导师发表的文章，并判断他的主要研究方向。

美国化学文摘社北京代表处

010-62508026

china@acs-i.org

